

- WEBINAR -

What is the place of long-acting GH in the management of pediatric and adult patients?

Thursday, 8 April 2021, 4pm CET

(check your local time on the registration link)

Join key opinion leaders to become familiar with the rapidly changing field of GH treatment, particularly regarding the move to promoting patient adherence and improving quality of life through the use of long-acting GH molecules.

During this session, Dr. Reiko Horikawa (Japan) and Dr. Kevin Yuen (USA) will:

- 1. Review the long-acting GH molecules currently being tested
- 2. Give an overview of the phase 3 trial results available for pediatric and adult patients with GH deficiency
- Discuss issues of safety, tolerability and efficacy in regard to who to put on long-acting GH
- 4. Identify what patients could benefit the most from receiving long-acting GH

The session will be moderated by Dr. Gudmundur Johannsson (Sweden).

Save the date and register today on the link below!



Register for the Webinar >>

This activity is supported by an unrestricted educational grant from Pfizer.

Pfizer is a global healthcare company, founded in 1849 and headquartered in New York, USA. Learn more about Pfizer here.



Do not hesitate to contact us at office@isendo.org if you have any questions or need further information.

The International Society of Endocrinology



Copyright © 2021 International Society of Endocrinology, All rights reserved.

You are receiving this email because you signed up to our mailing list, attended one of our events, or are otherwise affiliated with ISE.

Our mailing address is:

International Society of Endocrinology 7, Rue Francois-Versonnex Geneva 1207 Switzerland

Add us to your address book